Patients Rising Blog | Patient Stories, Policy Insights & News

The Priority Review Voucher, Explained: Why Some Rare Disease Treatments Get Built

Written by Patients Rising Staff | November 17, 2026 at 7:31 PM

Developing a medicine takes years and costs a fortune, and most of that money is spent before anyone knows whether it works. For a disease that affects a few hundred children, the math rarely adds up, so the treatment often never gets built. Twenty years ago, Duke economist David Ridley and two colleagues proposed a way to change that without asking taxpayers to pay for it. A year later Congress made it law. The latest episode of the State of the Patient podcast explains how it works, and what's at stake now.

Two medicines, one voucher

The priority review voucher always involves two medicines. A company that wins FDA approval for a treatment for a rare pediatric disease or a neglected tropical disease earns a voucher. That voucher entitles a second medicine, one with a much bigger market, to a faster FDA review, about six months instead of ten. Getting to market a few months sooner can be worth around $200 million, Ridley says, so the voucher can be used or sold, and that value is what draws investors to the first medicine. A priority review doesn't let a medicine skip any testing; it changes how quickly the FDA reads the paperwork once testing is done. On the episode, Ridley describes a Duke colleague whose treatment for a severe form of DiGeorge syndrome reached patients because the voucher brought investors to the table.

Does it work?

The episode keeps the counter-evidence in. By the American Society of Gene and Cell Therapy's count, the FDA has awarded 63 rare pediatric vouchers across 47 diseases, and only four of those diseases had an approved treatment before the program began. A 2019 study in Health Affairs reported that it hadn't found an increase in new rare pediatric medicines entering clinical trials after the program started. Ridley reads the same data differently, pointing to an increase from early to mid-stage trials and arguing that the tiny number of companies working on any one rare disease makes statistical proof hard to come by. Congress has asked the Government Accountability Office to study the program.

Waiting on Congress

The rare pediatric voucher has never been permanent. The FDA's authority to grant new rare pediatric designations lapsed in December 2024 and wasn't restored until February 2026, with a new expiration date of September 30, 2029. Ridley expects Congress to renew it again but worries about last-minute brinkmanship, because investors often wait for renewal before funding late-stage trials.

What's moving

In October, Stanford's Mussallem Center for Biodesign published a Roadmap for FDA Modernization by Rohini Kosoglu and Ryan Long. Among its twelve bipartisan ideas: make the rare pediatric voucher permanent; give patients and caregivers a documented role in deciding what a meaningful result looks like in a trial; and let patient organizations build natural history datasets the FDA has qualified, so future programs in a disease don't have to start from scratch. Julie Breneiser of the Gorlin Syndrome Alliance explains on the episode why that matters: for a community where some people have had more than a thousand basal cell carcinomas, a treatment that worked 30% of the time would be a big difference.

As Ridley put it, "If you're shooting a hundred percent, you're not shooting enough."

Listen to the full episode and read the transcript: Episode 10: More Shots on Goal